NeuroNova awarded grant to fund clinical trial of Parkinson’s disease treatment

Stockholm, Sweden, January 2008

NeuroNova AB received a SEK 4.9 million grant from VINNOVA, the Swedish Governmental Agency for Innovation Systems, to fund a clinical trial to evaluate sNN0031 in the treatment of Parkinson's disease.

The first-in-human study will evaluate the safety and tolerability of sNN0031in patients with Parkinson's disease. Treatment will be given for two weeks followed by a ten week post-treatment observation period. If the treatment is demonstrated to be safe and well tolerated, subsequent studies will focus on therapeutic efficacy.

sNN0031 is a novel drug candidate for Parkinson's disease that is designed to act on neural stem and progenitor cells in the brain. In preclinical studies, treatment with sNN0031 restores motor function and improves neurochemical deficits. The product is comprised of the naturally occurring protein PDGF-BB (platelet-derived growth factor BB) formulated for intracerebroventricular delivery. sNN0031 holds the potential to halt and even reverse disease progression, a much-needed improvement over currently available treatments, which only address the symptoms of Parkinson's disease.

About VINNOVA

VINNOVA (The Swedish Governmental Agency for Innovation Systems) is a State authority that aims to promote growth and prosperity throughout Sweden. VINNOVA's particular area of responsibility comprises innovations linked to research and development.

About NeuroNova AB

NeuroNova is a biopharmaceutical company engaged in the development of novel therapies for the treatment of disorders of the central nervous system (CNS). NeuroNova has two drug candidates nearing clinical development for Parkinson's disease and amyotrophic lateral sclerosis (ALS), and further promising compounds in discovery and preclinical development. As the projects progress through the drug development pipeline, NeuroNova intends to realize value by out-licensing and partnering with other biopharmaceutical companies. In some cases, NeuroNova may retain full rights to market a product in specific countries.

For more information, please contact:
Ulf Ljungberg, CEO
Phone: +46 (0)8786 09 00
ulf.ljungberg@neuronova.comThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Markus Jerling, CMO
Phone: +46 (0)8786 09 00
markus.jerling@neuronova.com